Kindai University — Biomedical Watch V2

Traitements3programmes

Essais1liés

Publications0liées

SourceDBlocale

Traitements

3

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
12-month DAPTThe aim of this study is to evaluate the safety of prasugrel monotherapy without aspirin versus 12-month dual antiplatelet therapy (DAPT) in patients with STEMI using platinum-chrome everolimus-eluting stent (PtCr-EES: SYNERGYTM).	Maladie coronarienne	Phase 4	À vérifier	Japan	À vérifier
No aspirin (Prasugurel monotherapy)The aim of this study is to evaluate the safety of prasugrel monotherapy without aspirin versus 12-month dual antiplatelet therapy (DAPT) in patients with STEMI using platinum-chrome everolimus-eluting stent (PtCr-EES: SYNERGYTM).	Maladie coronarienne	Phase 4	À vérifier	Japan	À vérifier
No aspirin (Prasugurel monotherapy)The aim of this study is to evaluate the safety of prasugrel monotherapy without aspirin versus 12-month dual antiplatelet therapy (DAPT) in patients with STEMI using platinum-chrome everolimus-eluting stent (PtCr-EES: SYNERGYTM).	Maladie coronarienne	Phase 4	À vérifier	Japan	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
No aspirin (Prasugurel monotherapy)	Maladie coronarienne	Phase 4	NCT05709626	PREMIUM — PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction	COMPLETED

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.